Stockholders' Equity - Additional Information (Details) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 01, 2022	Oct. 20, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Oct. 21, 2021
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized			100,000,000		100,000,000		100,000,000	100,000,000
Common stock, par value			$ 0.001		$ 0.001		$ 0.001	$ 0.001
Aggregate intrinsic value of stock options exercised					$ 0	$ 0
Fair value of options vested					$ 2,900,000	$ 5,100,000
Weighted average grant date fair value					$ 2.11	$ 7.07
Unrecognized stock-based compensation expense			$ 5,900,000		$ 5,900,000
Unrecognized stock-based compensation expense, weighted-average recognition period					2 years 2 months 12 days
Repurchase of common stock					0	0
Shares subject to repurchase					227,507		377,709
Aggregate exercise prices of early exercised shares					$ 100,000		$ 200,000
Preferred stock, shares authorized			5,000,000		5,000,000		5,000,000	5,000,000
Preferred stock, par value			$ 0.001		$ 0.001		$ 0.001	$ 0.001
Common stock available for future grants			472,104		472,104		1,934,095
Risk-free interest rate			2.80%
Dividend rate			0.00%	0.00%	0.00%	0.00%
Expected term			6 years		6 years
Volatility			72.20%
Compensation expense			$ 1,977,000	$ 1,075,000	$ 5,176,000	$ 5,684,000
ESPP
Subsidiary or Equity Method Investee [Line Items]
Common stock available for future grants		401,164
Number of predicted shares		468,959
Maximum percentage of eligible compensation		15.00%
Purchase of common stock grant date share value		$ 25,000,000
Purchase price of common stock, percentage		85.00%
Compensation expense			100,000		200,000
Restricted Stock Units
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense			3,500,000		$ 3,500,000
Unrecognized stock-based compensation expense, weighted-average recognition period					2 years 9 months 18 days
Number of shares, Granted					1,485,629
Compensation expense			852,000		$ 1,982,000
Tranche One | ESPP
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense, weighted-average recognition period					1 month 6 days
Risk-free interest rate	2.15%
Dividend rate	0.00%
Expected term	6 months
Volatility	74.52%
Tranche Two | ESPP
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense			200,000		$ 200,000
Unrecognized stock-based compensation expense, weighted-average recognition period					1 year
Risk-free interest rate	2.15%
Dividend rate	0.00%
Expected term	1 year
Volatility	65.14%
Maximum
Subsidiary or Equity Method Investee [Line Items]
Expected term				6 years		6 years
Maximum | ESPP
Subsidiary or Equity Method Investee [Line Items]
Purchase shares of common stock		10,000
Maximum | Tranche One | ESPP
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense			$ 100,000		$ 100,000
Minimum
Subsidiary or Equity Method Investee [Line Items]
Expected term				5 years		5 years